The PASI 90 rate, which is in line with the phase 2 result, looks competitive. Cross-trial comparisons can be unreliable, ...

The drug programs left behind after Jazz Pharmaceuticals' $820 million acquisition of Actio Biosciences have found a new home ...

AstraZeneca has punted a pair of early-phase prostate cancer progra | AstraZeneca has punted a pair of early-phase prostate ...

Roche announced the global launch of its VENTANA BAP1 (SP527) test, an automated, ready-to-use immunohistochemistry (IHC) assay . The highly specific diagnostic tool is designed to help clinicians and ...

With the U.S. patent on the immunology megablockbuster Dupixent set to expire in 2031, time is running out for Sanofi to find ...

Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...

Bristol Myers Squibb has scrapped a phase 1 program it licensed from Prothena for $80 million. | Bristol Myers Squibb has ...

BioMarin is paying $70 million upfront to license a Fabry disease drug candidate, expanding the franchise it acquired through ...

Flagship Pioneering unveiled Etcelera today, a new AI-powered biotech emerging from stealth that aims to predict how potential medicines will act in patients.

Scientists have known for a while that Angelman syndrome is caused by the loss of a specific gene, but they didn't understand ...

At Week 12 of its own phase 1b diabetes study, Lilly reported weight loss of up to 5.8 kg on Foundayo, compared to a 0.5 kg ...

Genmab acquired the immunoglobulin G1 bispecific antibody through its $8 billion acquisition of Merus last year. Petosemtamab binds both epidermal growth factor receptor (EGFR) and leucine-rich repeat ...